Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
Patient organizations applaud strong actions to protect people with pre-existing conditions
“President Biden’s actions this week represent a significant first step towards improving access to high-quality health coverage for people with pre-e…
News
FDA Approval of New CAR T-Cell Therapy Further Solidifies Immunotherapy as a Mainstay in Cancer Treatment
The U.S. Food and Drug Administration (FDA) today announced approval of a new CAR T-cell treatment for adult patients with certain forms of relapsed/r…
NexImmune Announces Pricing of Upsized Initial Public Offering
NexImmune, Inc., a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to gene…
News
Burlington Stores & its Customers Raise Nearly $4 Million for The Leukemia & Lymphoma Society (LLS) in the Fight Against Blood Cancer
The Leukemia & Lymphoma Society (LLS), the global leader in the fight against blood cancer, and Burlington Stores, the national retailer delivering am…
Research
European Commission Approves ELZONRIS for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
FLORENCE, January 21, 2021 – The Menarini Group, a privately held Italian pharmaceutical and diagnostics company, announced today that the European Co…
News
FDA Approval: Treatment Advance for Patients with Rare Blood Cell Disorder
On January 15, the U.S. Food and Drug Administration (FDA) announced approval of daratumumab plus hyaluronidase (Darzalex Faspro®) for adults with new…
News
The Leukemia & Lymphoma Society Applauds Bipartisan Agreement to Stop Surprise Medical Bills
Patients are now one step closer to breathing a sigh of relief. For too long, they’ve faced the anxiety of knowing that any visit to a healthcare prov…
News
FDA APPROVAL: TREATMENT ADVANCE FOR PATIENTS WITH MULTIPLE MYELOMA
The U.S. Food and Drug Administration (FDA) today announced approval of selinexor (Xpovio®) for adults with multiple myeloma who have had at least one…
News
Collaboration Driving Progress: LLS Forms Alliances with Leading Cancer Institutions and Foundations to Co-Fund nearly $17 million in New Research Grants
As the world confronts a viral pandemic not seen in the past 100 years, the reverberations are being felt across every sector, from healthcare to the …
BioTheryX Presented Trial in Progress at ASH: A Phase I Trial of BTX-A51 in Patients with AML or High-Risk MDS
Chappaqua, N.Y., December 7, 2020 - BioTheryX, Inc., a clinical stage biotechnology company creating new classes of compounds based on multi-kinase in…
Sutro Biopharma Presents Data for STRO-001 for the Treatment of NHL and AML at ASH
SOUTH SAN FRANCISCO, Calif., Dec. 7, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing compa…
Kymera Therapeutics Presents Preclinical Data on IRAKIMiD and STAT3 Programs at ASH
WATERTOWN, Mass., Dec. 07, 2020 - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deli…
For all media-related inquiries and interview requests please email
mediarelations@bloodcancerunited.org
A Blood Cancer United representative will respond as soon as possible.
